Arsenic Trioxide Combined With Chemotherapy for the Treatment of p53-mutated Pediatric Cancer
Status:
Recruiting
Trial end date:
2031-12-14
Target enrollment:
Participant gender:
Summary
This prospective, single-arm, multi-center clinical trial aims to explore and evaluate the
efficacy and safety of arsenic trioxide combined with chemotherapy for pediatric cancer with
p53 mutation.